Vigil Neuroscience’s (VIGL) “Buy” Rating Reaffirmed at Guggenheim

Guggenheim reaffirmed their buy rating on shares of Vigil Neuroscience (NASDAQ:VIGL) in a research report report published on Friday morning,Benzinga reports.

Several other analysts also recently weighed in on VIGL. Wedbush raised their target price on Vigil Neuroscience from $23.00 to $24.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. HC Wainwright restated a “buy” rating and set a $17.00 price objective on shares of Vigil Neuroscience in a research note on Thursday. William Blair started coverage on Vigil Neuroscience in a research report on Wednesday, December 4th. They issued an “outperform” rating on the stock. Finally, JMP Securities reissued a “market outperform” rating and set a $22.00 price target on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $19.75.

Vigil Neuroscience Price Performance

Vigil Neuroscience stock opened at $2.20 on Friday. Vigil Neuroscience has a one year low of $1.49 and a one year high of $6.06. The stock’s 50 day moving average price is $2.10 and its 200 day moving average price is $3.12.

Vigil Neuroscience (NASDAQ:VIGL) last posted its earnings results on Thursday, November 7th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.08. As a group, research analysts predict that Vigil Neuroscience will post -2.07 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in VIGL. Point72 Asset Management L.P. raised its stake in Vigil Neuroscience by 7.7% during the third quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company’s stock worth $5,440,000 after acquiring an additional 115,000 shares during the period. abrdn plc raised its position in shares of Vigil Neuroscience by 124.9% during the 4th quarter. abrdn plc now owns 528,472 shares of the company’s stock worth $898,000 after purchasing an additional 293,461 shares during the period. Ensign Peak Advisors Inc lifted its holdings in shares of Vigil Neuroscience by 72.8% in the 2nd quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock worth $1,580,000 after purchasing an additional 166,442 shares during the last quarter. Geode Capital Management LLC boosted its position in Vigil Neuroscience by 41.9% during the 3rd quarter. Geode Capital Management LLC now owns 226,083 shares of the company’s stock valued at $769,000 after purchasing an additional 66,712 shares during the period. Finally, Verition Fund Management LLC bought a new position in Vigil Neuroscience during the 3rd quarter worth $442,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.